Leading Companies in India Lisinopril Market | Competitive Landscape 2026

India Lisinopril Market Overview

According to 6Wresearch, the India lisinopril market is projected to grow steadily, supported by its status as a foundational therapy for hypertension, congestive heart failure, and post-myocardial infarction recovery. As a water-soluble ACE inhibitor with a predictable metabolic profile, lisinopril remains a staple in government health tenders and private retail pharmacies. The growing geriatric population, as well as the expansion of the "Pradhan Mantri Bhartiya Janaushadhi Pariyojana" (PMBJP) plan, which prioritizes the provision of high-quality, low-cost generic cardiovascular drugs, are driving market growth.

Competitive Landscape

The competitive landscape of the India lisinopril market is defined by aggressive generic pricing and a focus on fixed-dose combinations (FDCs). Leading firms are increasingly pairing lisinopril with diuretics (like hydrochlorothiazide) or calcium channel blockers (like amlodipine) to improve patient compliance.

Below is a list of leading players operating in the India Lisinopril Market:

1. Sun Pharmaceutical Industries Ltd.

Markets the prominent "Listril" brand; leverages its massive field force and recent acquisition of Taro Pharma to maintain dominance in both domestic and regulated generic markets.

2. Lupin Limited

A global leader in cardiovascular therapy, Lupin utilizes its high-capacity manufacturing sites to supply lisinopril formulations to the US and Indian markets simultaneously.

3. Cipla Limited

Offers lisinopril under the "Lipril" brand, focusing on affordability and broad availability through its extensive "Cipla-Genmed" division catering to tier-2 and tier-3 cities.

4. Zydus Lifesciences Limited

A key player in the chronic care segment, Zydus focuses on integrated manufacturing of ACE inhibitors to ensure cost-competitiveness in public health procurement.

5. Aurobindo Pharma Limited

One of India's largest exporters of generic lisinopril, Aurobindo relies on its vertical integration to control the entire production cycle from API to finished dosage.

6. Dr. Reddy’s Laboratories Ltd.

Focuses on value-added generics and process innovation to minimize impurities in antihypertensive batches, ensuring high patient safety standards.

7. Torrent Pharmaceuticals Ltd.

Strongly positioned in the cardiovascular segment with a focus on specialist-driven prescriptions and premium generic branding for chronic therapy.

8. Alembic Pharmaceuticals Ltd.

Utilizes a century of manufacturing heritage to produce high-volume lisinopril tablets, maintaining a significant presence in domestic retail channels.

9. Glenmark Pharmaceuticals Ltd.

Known for its focus on metabolic and cardiovascular health, Glenmark markets various dosage strengths to allow for precise titration in hypertensive patients.

10. Micro Labs Limited

A dominant force in the South Indian market, Micro Labs emphasizes physician education and clinical data to support its cardiovascular portfolio.

11. Ipca Laboratories Limited

Maintains a vertically integrated setup for several cardiovascular drugs, ensuring a steady supply of high-purity raw materials for its lisinopril range.

12. Mankind Pharma Limited

Captures the mass market through its aggressive pricing strategy and deep penetration into rural "rurban" healthcare centers.

13. Metrochem API Private Limited

A specialized B2B manufacturer that supplies Lisinopril Dihydrate API to major formulation companies across India and international markets.

14. Medico Remedies Ltd.

Focuses on the export and contract manufacturing of lisinopril tablets, catering to global health tenders and international generic requirements.